Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
The patient had a high-grade DCIS with necrosis, but a 0.9 DCSionRT score
Answer from: Radiation Oncologist at Community Practice
For now, I have been only omitting/discussing omission if both, clinical path and molecular test are concordant.
Sign in or Register to read more
21306
Related Questions
In cT4aN0 triple negative breast cancer would you still recommend PMRT if pCR, ypT0N0(sn), after neoadj chemo is achieved?
Is Behcet's disease a contraindication to breast conserving therapy?
What is the earliest you would start postmastectomy radiation after adjuvant chemotherapy for a patient with breast cancer?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
Under what circumstances would you offer PMRT in a patient with DCIS?
Would you offer partial breast radiation for bilateral DCIS?
What is your preferred sequencing of adjuvant chemotherapy and PMRT for node + breast cancer?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?